Retrospective Evaluation of Intravenous Fosfomycin in Multi-drug Resistant Infections at A Tertiary Care Hospital in İstanbul



Abstract Views
270

Downloads
259

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Apr 13, 2023
Published Jun 30, 2023
10.24018/clinicmed.2023.4.3.285

Abstract viewed = 270 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Introduction: Fosfomycin has started to be used again as a possible therapeutic alternative in cases injected with resistant bacterial pathogens. Its primary mechanism of action is inhibition of the first step of cell wall synthesis; This mechanism is effective against both Gram-positive and Gram-negative bacterial groups. However, its clinical efficacy against bacteria that develop multidrug resistance is largely unknown. Therefore, we aimed to evaluate the clinical and microbiological efficacy of intravenous Fosfomycin in a tertiary care center.
Methods: The group of adult patients aged 18 years and over who applied to the hospital between January 2018 and December 2022 and were given intravenous fosfomycin therapy for at least 24 hours due to any infection were retrospectively analyzed.
Results: 71 patients were included in our study. The female/male ratio of these patients was 35/36, and the mean age was 61.5±17.0 (18-84). The avarage time to treatment was 10.6 days (11.3-+11.4). 22 patients (31%) from Intensive Care Unit and 49 (69%) patients from other clinics were included in the study. 18 bacteremia (26%), 15 pneumonia (21%), 14 wound infections (19%), 13 ventilator-associated pneumonia (18%), 5 urinary tract infections (UTI) (8%), 4 abdominal infections (6%) and 2 endocarditis (3%). Detected causative microorganisms were 18 Extensively Drug-Resistant (XDR) Klebsiella pneumoniae, pandrug resistan Klebsiella pneumoniae (17.5%), 5 MRSA (12.5%), 5 pandrug resistan Pseudomonas aerinosa (12%), 4 Escherichia coli (10%), 1 Acinetobacterbaumanii (2.5%) and 1 Enterobacter spp. (2.5%). Looking at the underlying diseases, one of our patients had diabetes mellitus and another patient had chronic renal failure. Mean procalcitonin (PCT) and C reaktive protein (CRP) (cutoff value0.5 ng/mL) values were 2.53±1.2 ng/ml and 89.7±21.9 mg/dl, respectively. Median sodium (Na), potassium (K), AST, ALT, and creatinine values of the patients before and after fosfomycin IV treatment were calculated and there was no statistically significant difference.
Clinics combined with fosfomycin IV were as follows: 31 meropenem (44%), 15 colistin (26%), 18 tigecycline (26%), 3 vancomycin (4%), 3 amikacin (4%) and 1 daptomycin (1%).
Conclusions: According to the results of our study, it was seen that Fosfomycin is a safe and effective option in the treatment of multidrug-resistant infections. Accordingly, our results are compatible with the literature.

Keywords: Fosfomycin multidrug-resistant bacteria

References

  1. Sastry S, Doi Y. Fosfomycin: Resurgence of an old companion. J Infect Chemother. 2016; 22(5): 273-80.
     Google Scholar
  2. Gupta K, Hooton TM, Naber KG. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52(5): e103-20.
     Google Scholar
  3. Barry AL, Brown S Antibacterial spectrum of fosfomycin trometamol. J Antimicrob Chemother. 1995; 35: 228-30.
     Google Scholar
  4. Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C, Touw DJ, Stevens J, Kamerlin Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics. 2017; 6: 24.
     Google Scholar
  5. Centers for Disease Control and Prevention Antibiotic Resistance Threats in the United States, 2019.
     Google Scholar
  6. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL “Old” antibiotics for emerging multidrug-resistant bacteria. Curr Op in Infect Dis. 2012; 25: 626–33.
     Google Scholar
  7. Kaase M, Szabados F, Anders A, Gatermann SG. Fosfomycin susceptibility in carbapenem-resistant enterobacteria ceae from Germany. J Clin Microbiol. 2014; 52: 1893-7.
     Google Scholar
  8. GrabeinB, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB Intravenous fosfomycin back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017; 23: 363-72.
     Google Scholar
  9. Clinical and Laboratory Standards Institute (CLSI) M100 Performance Standards for Antimicrobial Susceptibility Testing. 27th. Wayne, PA, USA: Clinical and Laboratory Standards Institute.
     Google Scholar
  10. European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2017.
     Google Scholar
  11. Evren E, Azap OK, Çolakoğlu Ş, Arslan H. Invitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis. 2013; 76(3): 335-8.
     Google Scholar
  12. Falagas ME, Kanellopoulou MD, Karageorgopoulos DE, Dimopoulos G, Rafailidis PI, Skarmoutsou ND, et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 439-443.
     Google Scholar
  13. Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug- resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int. J. Antimicrob. Agents. 2010; 35: 240-243.
     Google Scholar
  14. Paterson DL. Serious infections in the intensive care unit: Pseudomonas aeruginosa and Acinetobacter baumannii. Clin. Infect. Dis. 2006; 43: S41-S42.
     Google Scholar
  15. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: A systematic review of microbiological, animal and clinical studies. Int. J. Antimicrob. Agents. 2009; 34: 111-120.
     Google Scholar
  16. Dinh A, Salomon J, Bru JP,Bernard L. Fosfomycin: Efficacy against infections caused by multidrug-resistant bacteria. Scand. J. Infect. Dis. 2012; 44: 182-189.
     Google Scholar
  17. Faruqi S, McCreanor J, Moon T, Meigh R, Morice AH. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis. Int. J. Antimicrob. Agents. 2008; 32: 461-463.
     Google Scholar
  18. Lu CL, Liu CY, Huang YT, Liao CH, Teng LJ, Turnidge JD, et al. Antimicrobial Susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods. Antimicrob. Agents Chemother. 2011; 55: 4295-4301.
     Google Scholar
  19. Walsh CC, Landersdorfer CB, McIntosh MP, Peleg AY, Hirsch EB, Kirkpatrick CM, Bergen PJ. Clinically relevant concentrations of fosfomycin combined with polymyxin B, tobramycin or ciprofloxacin enhance bacterial killing of Pseudomonas aeruginosa, but do not suppress the emergence of fosfomycin resistance. J. Antimicrob. Chemother. 2016; 71: 2218-2229.
     Google Scholar
  20. Kaye KS, Rice LB, Dane A, Stus V, Sagan O, Fedosiuk E, DasA, Skarinsky D, Eckburg PB, Ellis Grosse EJ. Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019; 27; 69(12): 2045-2056.
     Google Scholar
  21. Michalopoulos AS, Livaditis IG, Gougoutas V. Therevival of fosfomycin. Int J Infect Dis. 2011;15(11):e732-9.
     Google Scholar
  22. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ Fosfomycin. Clin Microbiol Rev. 2016; 29(2): 321-47.
     Google Scholar
  23. Grabein B, Graninger W, Rodriguez Bano J, Dinh A, Liesenfeld DB. Intravenous fosfomycin back to the future. Systematic review and meta analysis of the clinical literature. Clin Microbiol Infect. 2017; 23: 363-372.
     Google Scholar